News | May 15, 2021
Cipla reports Q4FY21 consolidated net profit of Rs. 413.38 Cr
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Subscribe To Our Newsletter & Stay Updated
